Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
Arch Dermatol Res ; 316(6): 316, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38822884

ABSTRACT

In the present study, we have formulated a methotrexate (MTX)-loaded microemulsion topical gel employing quality-by-design optimization. The optimized lipid-based microemulsion was incorporated into a 2% carbopol gel. The prepared formulation was characterized for micromeritics, surface charge, surface morphology, conductivity studies, rheology studies, texture analysis/spreadability, drug entrapment, and drug loading studies. The formulation was further evaluated for drug release and release kinetics, cytotoxicity assays, drug permeation and drug retention studies, and dermatokinetics. The developed nanosystem was not only rheologically acceptable but also offered substantial drug entrapment and loading. From drug release studies, it was observed that the nanogel showed higher drug release at pH 5.0 compared to plain MTX, plain gel, and plain microemulsion. The developed system with improved dermatokinetics, nanometric size, higher drug loading, and enhanced efficacy towards A314 squamous epithelial cells offers a huge promise in the topical delivery of methotrexate.


Subject(s)
Drug Liberation , Emulsions , Gels , Methotrexate , Skin Absorption , Methotrexate/administration & dosage , Methotrexate/chemistry , Methotrexate/pharmacokinetics , Humans , Skin Absorption/drug effects , Rheology , Lipids/chemistry , Administration, Cutaneous , Skin/metabolism , Skin/drug effects , Administration, Topical , Drug Delivery Systems/methods , Animals , Particle Size , Drug Carriers/chemistry , Nanogels/chemistry
2.
Arch Med Res ; 55(2): 102966, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38330831

ABSTRACT

BACKGROUND AND AIM: The increasing dilemma of multidrug-resistant cancer cells in response to currently available chemotherapeutic drugs and their associated side effect(s), calls for the investigation of alternative anticancer advances and molecules. Therefore, the present study aimed to elucidate the combinatorial potential against colon cancer of human defensin 5 in combination with 5-fluorouracil (5-FU), and against 5-FU resistant colon tumor cells. METHODS: The in vivo combinatorial potential of HD-5 with 5-FU was elucidated in terms of tumor morphometrics, apoptosis assay, surface morphology histology of the colon(s), and transcriptional alterations. Changes in membrane dynamics with mucin expression were evaluated by fluorescence microscopy and histochemistry. The in vitro activity of the peptide/drug conjunction was explored by phase contrast microscopy, MTT, LDH assay, and AO/EtBr staining. Chemoresistance to 5-FU was determined by phase contrast microscopy, MTT assay, annexin V-FITC/PI flow cytometry, and MDR-1, Bak, and Bax expression. RESULTS: In vivo decreases in tumor parameters, with a marked increase in apoptosis and neutrophil infiltrations indicated restoration of normal architecture with improved mucin content in the treated colons. This happened with substantial changes in key molecular markers of the intrinsic apoptotic cascade. Membrane dynamics revealed that peptides and chemotherapeutic drugs could bind to cancerous cells by taking advantage of altered levels of membrane fluidity. CONCLUSION: Peptide treatment of drug-resistant Caco-2 cells promotes enhanced 5-FU uptake, in contrast to when cells were treated with 5-FU alone. Hence, HD-5 as an adjunct to 5-FU, exhibited strong cancer cell killing even against 5-FU-resistant tumorigenic cells.


Subject(s)
Colonic Neoplasms , Fluorouracil , Protein Precursors , Humans , Fluorouracil/pharmacology , Drug Resistance, Multiple , Caco-2 Cells , Cell Line, Tumor , Drug Resistance, Neoplasm , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Apoptosis , Peptides/therapeutic use , Mucins/therapeutic use
3.
Int J Pept Res Ther ; 29(4): 61, 2023.
Article in English | MEDLINE | ID: mdl-37251528

ABSTRACT

In recent years, the occurrence of a wide variety of drug-resistant diseases has led to an increase in interest in alternate therapies. Peptide-based drugs as an alternate therapy hold researchers' attention in various therapeutic fields such as neurology, dermatology, oncology, metabolic diseases, etc. Previously, they had been overlooked by pharmaceutical companies due to certain limitations such as proteolytic degradation, poor membrane permeability, low oral bioavailability, shorter half-life, and poor target specificity. Over the last two decades, these limitations have been countered by introducing various modification strategies such as backbone and side-chain modifications, amino acid substitution, etc. which improve their functionality. This has led to a substantial interest of researchers and pharmaceutical companies, moving the next generation of these therapeutics from fundamental research to the market. Various chemical and computational approaches are aiding the production of more stable and long-lasting peptides guiding the formulation of novel and advanced therapeutic agents. However, there is not a single article that talks about various peptide design approaches i.e., in-silico and in-vitro along with their applications and strategies to improve their efficacy. In this review, we try to bring different aspects of peptide-based therapeutics under one article with a clear focus to cover the missing links in the literature. This review draws emphasis on various in-silico approaches and modification-based peptide design strategies. It also highlights the recent progress made in peptide delivery methods important for their enhanced clinical efficacy. The article would provide a bird's-eye view to researchers aiming to develop peptides with therapeutic applications.

5.
J Microencapsul ; 39(7-8): 609-625, 2022.
Article in English | MEDLINE | ID: mdl-36472891

ABSTRACT

AIM: The present study aimed to develop topical combinatorial therapy of nisin and 5-fluorouracil in a single nanosized formulation against skin cancer. METHODS: Nisin and 5-fluorouracil were encapsulated in an organogel system (NF-OG) and investigated for morphology, physicochemical properties, cytotoxicity, encapsulation and release. NF-OG was evaluated against DMBA/TPA murine skin cancer in terms of tumour statistics, histoarchitecture, TUNEL and M1/M2 macrophages. RESULTS: The optimised NF-OG formulation exhibited particle size of 185.1 ± 11.24 nm, zeta potential of -7.93 ± 0.60 mV, offered substantial drug loading and temporal release. NF-OG therapy led to improved cytotoxicity of nisin and 5-FU against B16-F10 cells, significant decrease in tumour volume (84.983 mm3) in treated group as compared to untreated group (490.482 mm3) accompanied by restoration of histoarchitecture and repolarization of macrophages. CONCLUSION: The study yielded a promising delivery system exhibiting potent anticancer activity and forms the bases for further applications in clinical settings.


Subject(s)
Nanoparticles , Nisin , Skin Neoplasms , Mice , Animals , Fluorouracil , Nisin/pharmacology , Antimetabolites, Antineoplastic , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Particle Size , Nanoparticles/chemistry , Drug Carriers/chemistry
6.
Sci Rep ; 12(1): 12058, 2022 07 14.
Article in English | MEDLINE | ID: mdl-35835842

ABSTRACT

The emergence of multidrug resistance coupled with shrinking antibiotic pipelines has increased the demand of antimicrobials with novel mechanisms of action. Therefore, researchers across the globe are striving to develop new antimicrobial substances to alleviate the pressure on conventional antibiotic therapies. Host-Defence Peptides (HDPs) and their derivatives are emerging as effective therapeutic agents against microbial resistance. In this study, five analogs (DP1-5) of the N-terminal (N-15) fragment of CATH-2 were designed based on the delicate balance between various physicochemical properties such as charge, aliphatic character, amphipathicity and hydrophobicity. By means of in-silico and in-vitro studies a novel peptide (DP1) with the sequence "RFGRFLRKILRFLKK" was found to be more effective and less toxic than the N-terminal CATH-2 peptide. Circular dichroism spectroscopy and differential scanning calorimetry were applied for structural insights. Antimicrobial, haemolytic, and cytotoxic activities were also assessed. The resulting peptide was characterized by low cytotoxicity, low haemolytic activity, and efficient anti-microbial activity. Structurally, it displayed strong helical properties irrespective of the solvent environment and was stable in membrane-mimicking environments. Taken together, the data suggests that DP1 can be explored as a promising therapeutic agent with possible clinical applications.


Subject(s)
Anti-Infective Agents , Antimicrobial Peptides , Anti-Bacterial Agents/chemistry , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Antimicrobial Cationic Peptides/chemistry , Antimicrobial Cationic Peptides/pharmacology , Circular Dichroism , Hemolysis , Humans , Microbial Sensitivity Tests
7.
Int J Pharm ; 620: 121744, 2022 May 25.
Article in English | MEDLINE | ID: mdl-35427747

ABSTRACT

Cancer is a major health concern worldwide as conventional treatment modalities face several limitations such as drug resistance, toxicity etc. To overcome such deficits, combination therapy involving anticancer peptides and chemodrugs is being considered as an attractive strategy. Therefore, present study developed, characterized and evaluated the anticancer potential of a single nanoconstruct comprising of oligomeric chitosan coated silver nanoparticles co-loaded with nisin and 5-florouracil (5-FU/nisin-CHI-AgNPs) against DMBA/TPA-induced murine skin cancer. It was fabricated using wet reduction method of silver salt to form silver nanoparticles followed sequentially by oligomeric chitosan coating, nisin conjugation to deacetylated units of chitosan oligomers (EDC/NHS chemistry) and physical loading of 5-FU. Biophysical characterisation studies revealed that the developed nanoconstruct had UV-visible absorption maxima at 420 nm, zeta potential of + 32.90 mV and 72.39 nm particle size (TEM analysis). In vivo anticancer therapeutic potential was assessed in terms of tumor statistics, histopathological, scanning electron microscopic analyses and testing oxidant/antioxidant status which exhibited marked reduction both in mean tumor volume (68.34 %) and mean tumor burden (82.39 %); restored skin histoarchitecture and improved oxidant/antioxidant status. Interestingly, anticancer therapeutic potential of nisin and 5-florouracil was found to be enhanced in vivo when bound on single composite nanoconstruct. The study forms a basis for developing synergetic single platforms against variety of cancers.


Subject(s)
Chitosan , Metal Nanoparticles , Nanoparticles , Nisin , Skin Neoplasms , Animals , Antioxidants , Chitosan/chemistry , Fluorouracil , Metal Nanoparticles/chemistry , Mice , Nanoparticles/chemistry , Nisin/pharmacology , Oxidants , Particle Size , Silver/pharmacology , Skin Neoplasms/drug therapy
8.
Colloids Surf B Biointerfaces ; 211: 112303, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34952285

ABSTRACT

The decreasing effectiveness of conventional drugs due to multidrug-resistance is a major challenge for the scientific community, necessitating development of novel antimicrobial agents. In the present era of coronavirus 2 (COVID-19) pandemic, patients are being widely exposed to antimicrobial drugs and hence the problem of multidrug-resistance shall be aggravated in the days to come. Consequently, revisiting the phenomena of multidrug resistance leading to formulation of effective antimicrobial agents is the need of the hour. As a result, this review sheds light on the looming crisis of multidrug resistance in wake of the COVID-19 pandemic. It highlights the problem, significance and approaches for tackling microbial resistance with special emphasis on anti-microbial peptides as next-generation therapeutics against multidrug resistance associated diseases. Antimicrobial peptides exhibit exceptional mechanism of action enabling rapid killing of microbes at low concentration, antibiofilm activity, immunomodulatory properties along with a low tendency for resistance development providing them an edge over conventional antibiotics. The review is unique as it discusses the mode of action, pharmacodynamic properties and application of antimicrobial peptides in areas ranging from therapeutics to agriculture.


Subject(s)
COVID-19 , Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Humans , Microbial Sensitivity Tests , Pandemics , Peptides/pharmacology , SARS-CoV-2
9.
Braz J Microbiol ; 52(3): 1303-1313, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33851343

ABSTRACT

This study was focused on elucidating inhibition of antibiotic efflux mechanism of cadmium adapted (CdA) Salmonella Typhi Ty2 cells. Herein, upregulated expression of efflux genes (acrB, tolC) and their regulators (soxS, marA) was observed in CdA Ty2 cells by qRT-PCR. The pathogen further elevated the expression of these genes even in the presence of three efflux pump inhibitors (EPIs), i.e., Phe-Arg-ß-naphthylamide, 1-(1-naphthyl-methyl)piperazine, and 5-hydroxy-2-methyl-1,4-naphthoquinone, perhaps by sensing the pressure of the latter in addition to cadmium stress. Interaction of different EPIs with efflux pumps of CdA Ty2 cells was confirmed using ethidium bromide (EtBr) accumulation and efflux assay. All the EPIs could cause retention of EtBr which was indicated by increased fluorescence units. Considering this potential of EPIs, retention of antibiotics was evaluated in CdA Ty2 cells wherein EPIs were used in combination with selected antibiotics (instead of EtBr). A decrease in the effective concentration of antibiotics was observed. This was further validated using the clinical isolates. The data revealed the efficiency of EPIs as they could inhibit the efflux potential of even the overexpressed efflux pumps. Thus, combination of EPI(s)-antibiotics may be exploited in future as one of the strategies for combating metal induced antibiotic resistance.


Subject(s)
Anti-Bacterial Agents , Cadmium , Drug Resistance, Multiple, Bacterial , Piperazine , Salmonella typhi , Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial/genetics , Microbial Sensitivity Tests , Piperazine/pharmacology , Salmonella typhi/drug effects , Salmonella typhi/genetics
10.
AAPS PharmSciTech ; 22(3): 130, 2021 Apr 09.
Article in English | MEDLINE | ID: mdl-33835327

ABSTRACT

Skin cancer is an alarming concern due to increased radiation and chemical exposure. Doxorubicin is a drug prescribed for various cancers by parenteral route. Apart from the pharmaceutical challenge of being a biopharmaceutical classification system (BCS) Class III drug, the side effects of doxorubicin are also a great concern. With an aim to enhance its safety and bioavailability, a phospholipid-based micellar system was developed. The developed nanometric and symmetric carriers not only offered substantial drug loading, but also offered a temporal drug release for longer durations. The pH-dependent drug release assured the spatial delivery at the target site, without loss of drug in the systemic circulation. The cancer cell toxicity studies along with the in vivo anti-tumor studies established the superior efficacy of the developed system. The blood profile studies and the biochemical estimations confirmed the safety of the developed nanocarriers. Lesser amount of drug was available for the microsomal degradation, as inferred by the biodistribution studies. The findings provide a proof of concept for the safer and effective doxorubicin delivery employing simple excipients like phospholipids for the management of skin cancer.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/therapeutic use , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Skin Neoplasms/drug therapy , Animals , Anthracenes , Antibiotics, Antineoplastic/pharmacokinetics , Carcinogens , Cell Line, Tumor , Doxorubicin/pharmacokinetics , Drug Carriers , Drug Delivery Systems , Female , Humans , Mice , Mice, Inbred BALB C , Micelles , Nanostructures , Particle Size , Phospholipids , Piperidines , Skin Neoplasms/chemically induced , Tissue Distribution
11.
Wound Repair Regen ; 29(5): 711-724, 2021 09.
Article in English | MEDLINE | ID: mdl-33721379

ABSTRACT

The emergence of multidrug resistant strains of Pseudomonas aeruginosa necessitates the exploration of novel therapeutic intervention (s). The present study aimed to develop a nisin loaded carbopol gel formulation (NLCG) and explore its therapeutic efficacy against P. aeruginosa infected burn wounds. The formulation was prepared using Carbopol 940 as a polymer and characterized in terms of its appearance, stability, pH, rheology, spreadability, release, and permeation profiles. Disc diffusion assay and field emission scanning electron microscopy were carried out to establish in vitro antibacterial activity while the in vitro cytotoxicity was evaluated by hemolytic and trypan blue exclusion assay. Furthermore, in vivo efficacy was investigated by developing P. aeruginosa infected third-degree murine burn wound model followed by evaluation of parameters like bacterial loads, skin restoration, histopathological architecture, levels of hydroxyproline, myeloperoxidase and cytokines. Our studies yielded a stable formulation with pH, viscosity and drug release flux values as 6.5 ± 0.02, 382.4 p and 160.55 ± 3.64 µg h-1  cm-2 , respectively. Approximately, 84.02 ± 1.63% of nisin was found to permeate into murine skin, further, affirmed by confocal microscopic observations. Interestingly, no in vitro cytotoxicity of NLCG (to erythrocytes and/or to peritoneal macrophages) could be observed. The log units decrease (s) in CFUs of Pseudomonas in skin were found to be 1.5137, 4.2257, 6.456 after 12, 24 and 72 h of topical gel therapy, respectively. Percentage wound closure, tensile strength, histological, and scanning electron microscopic studies further provided a healing evidence with skin showing restoration of the epithelium. The gel therapy also led to a significant modulation (p ≤ 0.05) in hydroxyproline content, myeloperoxidase levels, and serum levels of IL-1, IL-10, and TNF-α. Our formulation revealed anti-Pseudomonas, wound healing, and immunomodulatory efficacy of NLCG. Further investigations are warranted to determine the underlying mechanism (s) of these displayed antibacterial and immunomodulatory effects.


Subject(s)
Burns , Nisin , Acrylic Resins , Animals , Burns/drug therapy , Mice , Pseudomonas aeruginosa , Wound Healing
12.
Pharmacol Res ; 167: 105529, 2021 05.
Article in English | MEDLINE | ID: mdl-33675962

ABSTRACT

Despite recent advances in the treatment of colorectal cancer (CRC), low patient survival rate due to emergence of drug resistant cancer cells, metastasis and multiple deleterious side effects of chemotherapy, is a cause of public concern globally. To negate these clinical conundrums, search for effective and harmless novel molecular entities for the treatment of CRC is an urgent necessity. Since antimicrobial peptides (AMPs) are part of innate immunity of living beings, it is quite imperative to look for essential attributes of these peptides which may contribute to their effectiveness against carcinogenesis. Once identified, those characteristics can be suitably modified using several synthetic and computational techniques to further enhance their selectivity and pharmacokinetic profiles. Hence, this review analyses scientific reports describing the antiproliferative action of AMPs derived from several sources, particularly focusing on various colon cancer in vitro/in vivo investigations. On perusal of the literature, it appears that AMPs based therapeutics would definitely find special place in CRC therapy in future either alone or as an adjunct to chemotherapy provided some necessary alterations are made in their natural structures to make them more compatible with modern clinical practice. In this context, further in-depth research is warranted in adequate in vivo models.


Subject(s)
Antimicrobial Peptides/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinogenesis/drug effects , Colorectal Neoplasms/drug therapy , Animals , Antimicrobial Peptides/chemistry , Antimicrobial Peptides/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Carcinogenesis/immunology , Carcinogenesis/pathology , Colorectal Neoplasms/immunology , Colorectal Neoplasms/pathology , Humans , Immunity/drug effects
13.
Indian J Med Microbiol ; 38(2): 200-209, 2020.
Article in English | MEDLINE | ID: mdl-32883934

ABSTRACT

Purpose: Enterococci express high degree of resistance towards wide range of antibiotics. Production of biofilm and many virulence factors along with drug resistance makes it difficult to eradicate the infection from urinary tract. The present study detected the expression of such factors including biofilm production by multidrug-resistant (MDR) enterococci. Materials and Methods: Drug susceptibility of 103 uropathogenic enterococci was performed followed by estimation of minimum inhibitory concentration of high-level gentamicin and vancomycin by microbroth dilution method. Vancomycin-resistant genes were detected by multiplex polymerase chain reaction. Production of virulence factors such as haemagglutination, caseinase, lipase, gelatinase, haemolysin and ß-lactamase was detected by phenotypic methods in MDR strains. Biofilm production was detected by calcofluor-white fluorescence staining and semi-quantitative adherence assay. Results: 45% and 18.4% of the isolates were high-level gentamicin-resistant and vancomycin-resistant enterococci (VRE), respectively. vanA gene was detected in 14 and vanB gene in 5 strains. Biofilm, caseinase and gelatinase were the most expressed virulence factor. Expression of caseinase, gelatinase and lipase was significantly higher in Enterococcus faecalis (P < 0.05). Expression of haemagglutination, gelatinase and haemolysin among the vancomycin-resistant isolates was significantly higher (P < 0.05). Conclusion: VanA and vanB are the prevalent genotypes responsible for vancomycin resistance. The high prevalence of MDR enterococcal strains producing biofilm and virulence determinants raises concern. asa1, hyl, esp, gelE, cyl and other genes are known to express these factors and contribute to biofilm formation. Most uropathogenic enterococci expressed biofilm at moderate level and can be detected effectively by calcofluor-white staining. No correlation was noted between vancomycin resistance and biofilm production.


Subject(s)
Biofilms/growth & development , Enterococcus faecium/pathogenicity , Gram-Positive Bacterial Infections/microbiology , Urinary Tract Infections/microbiology , Vancomycin-Resistant Enterococci/pathogenicity , Virulence Factors/biosynthesis , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Carbon-Oxygen Ligases/genetics , Cross-Sectional Studies , Drug Resistance, Multiple, Bacterial , Enterococcus/drug effects , Enterococcus/isolation & purification , Enterococcus/metabolism , Enterococcus/pathogenicity , Enterococcus faecalis/drug effects , Enterococcus faecalis/isolation & purification , Enterococcus faecalis/metabolism , Enterococcus faecalis/pathogenicity , Enterococcus faecium/drug effects , Enterococcus faecium/isolation & purification , Enterococcus faecium/metabolism , Genes, Bacterial , Humans , India , Microbial Sensitivity Tests , Vancomycin Resistance/genetics , Vancomycin-Resistant Enterococci/genetics , Vancomycin-Resistant Enterococci/isolation & purification , Vancomycin-Resistant Enterococci/physiology , Virulence/genetics , Virulence Factors/genetics
14.
Int J Pharm ; 578: 119088, 2020 Mar 30.
Article in English | MEDLINE | ID: mdl-32001291

ABSTRACT

Docetaxel (DTX), a widely prescribed anticancer agent, is now associated with increased instances of multidrug resistance. Also, being a problematic BCS class IV drug, it poses challenges for the formulators. Henceforth, it was envisioned to synthesize an analogue of DTX with a biocompatible lipid, i.e., palmitic acid. The in-silico studies (molecular docking and simulation) inferred lesser binding of docetaxel palmitate (DTX-PL) with P-gp vis-à-vis DTX and paclitaxel, indicating it to be a poor substrate for P-gp efflux. Solid lipid nanoparticles (SLNs) of the conjugate were prepared using various lipids, viz. palmitic acid, stearic acid, cetyl palmitate and glyceryl monostearate. The characterization studies for the nanocarrier were performed for the surface charge, drug payload, micromeritics, release pattern of drug and surface morphology. From the cytotoxicity assays on resistant MCF-7 cells, it was established that the new analogue offered substantially decreased IC50 to that of DTX. Further, apoptosis assay also corroborated the results obtained in IC50 determination wherein, SA-SLNs showed the highest apoptotic index than free DTX. The conjugate not only enhanced the solubility but also offered lower plasma protein binding and improved pharmacokinetic and pharmacodynamic effect for DTX loaded SA-SLNs in apt animal models, and lower affinity to P-gp efflux. The studies provide preliminary evidence and a ray of hope for a better candidate in its nano version for safer and effective cancer chemotherapy.


Subject(s)
Antineoplastic Agents/administration & dosage , Docetaxel/administration & dosage , Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Lipids/administration & dosage , Mammary Neoplasms, Experimental/drug therapy , Nanoparticles/administration & dosage , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Apoptosis/drug effects , Cell Survival/drug effects , Docetaxel/chemistry , Docetaxel/pharmacokinetics , Drug Liberation , Erythrocytes/drug effects , Female , Humans , Lipids/chemistry , Lipids/pharmacokinetics , MCF-7 Cells , Male , Mice, Inbred BALB C , Nanoparticles/chemistry , Rats, Wistar , Serum Albumin, Human/chemistry
15.
Peptides ; 126: 170263, 2020 04.
Article in English | MEDLINE | ID: mdl-31981594

ABSTRACT

The escalating predicament of multidrug resistant cancer cells and associated side effects of conventional chemotherapy necessitates the exploration of alternative anticancer therapies. The present study evaluated anticancer therapeutic potential of human defensin 5 (HD-5) against colon cancer. The in vivo anticancer efficacy of HD-5 against 1,2-dimethylhydrazine (DMH) induced colon cancer was elucidated in terms of tumor biostatistics, number of aberrant crypt foci (ACF), in situ apoptosis assay,changes in morphological as well as histological architecture of colon(s). The direct interaction of peptide was investigated by incubating peptide with normal and/or cancerous colonocytes followed by phase contrast, Hoechst 3342 and AO/PI staining as well as confocal microscopy. Changes in membrane dynamics were evaluated by MC 540 and N-NBD-PE staining. In vivo decrease(s) in tumor parameters, number of aberrant crypt foci along with marked increase in the rate of apoptosis was observed.H&E staining revealed neutrophils infiltration and restoration of normal architecture in treated colon(s) which was consistent with scanning electron microscopic observations. Furthermore, non-membranolytic mechanism was found to be acquired by peptide as it could traverse cell membrane gaining access to nucleus and cytoplasm thereby disintegrating cellular architecture. MC 540 and NBD-PE staining revealed that peptide could bind to cancerous cells by taking advantage of altered fluidity levels. Our results indicated that HD-5 exhibited strong cancer cell killing and does not affect normal host cells. The peptide can be exploited as promising option to combat developing menace of colon cancer and/or can at least be used as an adjunct to present day chemotherapies.


Subject(s)
Colonic Neoplasms/prevention & control , Peptide Fragments/pharmacology , alpha-Defensins/pharmacology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Carcinogens/toxicity , Colon/drug effects , Colon/pathology , Colonic Neoplasms/chemically induced , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Dimethylhydrazines/toxicity , Female , Random Allocation , Rats , Rats, Sprague-Dawley
16.
Biochem Biophys Res Commun ; 520(3): 551-559, 2019 12 10.
Article in English | MEDLINE | ID: mdl-31615654

ABSTRACT

Chemotherapy, a gold standard for treating most of the cancers, involves drastic side-effects and multidrug resistance. An attractive alternative is development of combination therapy employing antimicrobial peptides with chemotherapeutic drugs. In vivo studies: Anti-cancer therapeutic efficacy of 5-fluororuacil (5-FU) in conjunction with nisin (50 mg/kg body weight) was evaluated against murine skin cancer, in terms of tumor biostatistics, histopathology, electron microscopy, infrared spectroscopy and transcriptional studies. In vitro studies: Dose and time dependent cytotoxicity of agents were assessed against A431 cell line using MTT assay, LDH assay and acridine orange/ethidium bromide dual staining. Significant percentage decrease(s) in mean tumor volume and tumor burden were observed in nisin+ 5-FU combination treated groups as compared to alone treated groups. Histoarchitecture of treated skins demonstrated restoration towards normal skin tissue (being highest in the combination group). Modulation of apoptotic, angiogenic and proliferative genes were observed in treated groups. IC50 of combination was found to be 2 µg/ml as compared to nisin alone (32µg/ml) and 5-FU alone (16µg/ml) with combination index of 0.188. Dual staining showed that rate of induction of apoptosis was higher in the combination group as compared to single agents. Nisin and 5-FU in combination were found to be synergistic both in vivo and in vitro.


Subject(s)
Fluorouracil/administration & dosage , Nisin/administration & dosage , Skin Neoplasms/drug therapy , Administration, Topical , Animals , Anti-Bacterial Agents/administration & dosage , Antineoplastic Agents/administration & dosage , Apoptosis/drug effects , Bacteriocins/administration & dosage , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Drug Synergism , Female , Humans , Injections, Subcutaneous , Mice , Mice, Inbred BALB C , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Xenograft Model Antitumor Assays
17.
Colloids Surf B Biointerfaces ; 176: 62-69, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-30594704

ABSTRACT

In recent years, there is significant growth in the bacterial resistance to various classic antibiotics. This has opened and enhanced the field of metal nanoparticles and antibiotic-metal nanoparticle complex. This research was designed to load a glycopeptide antibiotic named vancomycin on citrate-capped silver nanoparticles to enhance its antibacterial activity against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Colloidal solution of silver nanoparticles (AgNPs) was prepared by chemical reduction method using silver nitrate (AgNO3) as a precursor in the presence of ionic surfactant trisodium-citrate which acts as a both capping and reducing agent. Synthesized nanoparticles were functionalized with vancomycin to form nano-drug complex (Van@AgNPs). Various analytical techniques such as UV-vis absorption spectra, FTIR, DLS, TEM and XRD were carried out to study the loading and interaction of drug with silver nanoparticles. The observed shift in SPR peak of UV-vis and various reflections of XRD spectra is attributed towards the loading of vancomycin on silver nanoparticle surface. FTIR studies shows the hydrogen bonding between vancomycin and silver nanoparticles through NH (amine) group of vancomycin and oxygen of anionic citrate. The increase in average particle size and particle size distribution of vancomycin-loaded nanoparticles in comparison to bare NPs also hints the drug loading. Agar well diffusion method was used to study the synergetic antibacterial activity of vancomycin-loaded silver nanoparticles against both test strains. The well diffusion test showed the notable enhancement in antibacterial activity against both class of bacteria. This enhancement has been observed to be synergetic rather than the additive.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Metal Nanoparticles/chemistry , Silver/pharmacology , Staphylococcus aureus/drug effects , Vancomycin/pharmacology , Animals , Anti-Bacterial Agents/chemistry , Cell Survival/drug effects , Citric Acid/chemistry , Citric Acid/pharmacology , Macrophages/drug effects , Mice , Microbial Sensitivity Tests , Molecular Structure , Particle Size , Silver/chemistry , Surface Properties , Vancomycin/chemistry
18.
Sci Rep ; 8(1): 12818, 2018 08 24.
Article in English | MEDLINE | ID: mdl-30143701

ABSTRACT

In view of the reports on co-selection of metal and antibiotic resistance, recently we have reported that increased cadmium accumulation in Salmonella Typhi Ty2 leads to increased antibiotic resistance. In continuation, the present study was carried to substantiate this association in clinical isolates. Interestingly, the levels of cadmium were found to be more in the clinical isolates which co-related with their antibiotic sensitivity/resistance pattern. On cadmium accumulation, antibiotic(s) sensitive isolates were rendered resistant and the resistant isolates were rendered more resistant as per their minimum inhibitory concentration(s). Further, after subjecting the pathogen to cadmium accumulation, alterations occurring in the cells were assessed. Transgenerational cadmium exposure led to changes in growth response, morphology, proteome, elevated antioxidants other than SOD, increased biofilm formation, decreased intracellular macrophage killing coupled with upregulation of genes encoding metallothionein and metal transporters. Thus, these results indicate that cadmium, if acquired from the environment, being non-degradable can exert a long-lasting selective pressure on Salmonella in the host which may display antibiotic resistance later on, as a result of co-selection. Therefore, appropriate strategies need to be developed to inhibit such an enduring pressure of heavy metals, as these represent one of the factors for the emerging antibiotic resistance in pathogens.


Subject(s)
Cadmium/pharmacology , Drug Resistance, Microbial/drug effects , Salmonella enterica/physiology , Biofilms/drug effects , Gene Expression Regulation, Bacterial/drug effects , Microbial Sensitivity Tests , Salmonella enterica/growth & development , Salmonella enterica/isolation & purification , Salmonella enterica/ultrastructure , Superoxide Dismutase/metabolism
19.
Curr Pharm Des ; 24(43): 5147-5163, 2018.
Article in English | MEDLINE | ID: mdl-30727874

ABSTRACT

Despite the fact that protein and peptide therapeutics are widely employed in the treatment of various diseases, their delivery is posing an unembellished challenge to the scientists. It was discovered that delivery of these therapeutic systems through oral route is easy with high patient compliance. However, proteolytic degradation and absorption through the mucosal epithelium are the barriers in this route. These issues can be minimized by the use of enzyme inhibitors, absorption enhancers, different carrier systems or either by direct modification. In the process of investigation, it was found that transdermal route is not posing any challenges of enzymatic degradation, but, still absorption is the limitation as the outer layer of skin acts as a barrier. To suppress the effect of the barrier and increase the rate of the absorption, various advanced technologies were developed, namely, microneedle technology, iontophoresis, electroporation, sonophoresis and biochemical enhancement. Indeed, even these molecules are targeted to the cells with the use of cell-penetrating peptides. In this review, delivery of the peptide and protein therapeutics using oral, transdermal and other routes is discussed in detail.


Subject(s)
Drug Delivery Systems , Peptides/pharmacology , Pharmaceutical Preparations/metabolism , Proteins/metabolism , Animals , Humans , Peptides/administration & dosage , Peptides/chemistry , Pharmaceutical Preparations/administration & dosage , Pharmaceutical Preparations/chemistry , Proteins/administration & dosage , Proteins/chemistry
20.
Indian J Microbiol ; 57(4): 438-447, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29151645

ABSTRACT

Resurgence of sensitivity of the antibiotics, to which the pathogen had developed resistance in the past, requires special attention for strengthening the reservoir of antimicrobial compounds. Reports in the recent past have suggested that co-trimoxazole (COT) has regained its activity against methicillin resistant Staphylococcus aureus (MRSA). The present study exploited the use of COT in the presence of an antimicrobial peptide (AMP), cryptdin-2 (a murine Paneth cell alpha defensin), in order to reduce the selective pressure of the antibiotic on the pathogen. In vitro antibacterial activity and in vivo efficacy of the combination was ascertained against MRSA induced systemic infection using a murine model. Observations of the present study might help in restoring the regained activity of conventional antibiotics, such as COT, when used in combination with novel antimicrobial molecules like AMPs. This might prove as a viable strategy to eliminate the chances of re-occurrence of resistance due to their multi-prong targeting and synergistically combating infections caused by these resistant pathogens.

SELECTION OF CITATIONS
SEARCH DETAIL
...